--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 6, 2001 (September 6, 2001)
BioMarin Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)
Delaware 000-26727 68-0397820
(State or other jurisdiction (Commission (IRS Employer Identification
of incorporation) File Number) No.)
371 Bel Marin Keys Boulevard, 94949
Suite 210 (Zip Code)
Novato, California
(Address of principal
executive offices)
(415) 884-6700
(Registrant's telephone number, including area code)
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Item 5. Other Events
On September 6, 2001, we announced the completion and the preliminary results of
our Phase I clinical trial of recombinant human N-acetylgalactosamine
4-sulfatase (rhASB) for the treatment of MPS VI in a press release, dated
September 6, 2001. A copy of the press release is attached hereto as Exhibit
99.1 and incorporated herein by reference.
Item 7. Financial Statements and Exhibits
EXHIBIT NO. DESCRIPTION OF DOCUMENT
----------- ------------------------------------------------------------------
99.1 Press Release Dated September 6, 2001 related to completion of
MPS VI Phase I Trial.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BioMarin Pharmaceutical Inc.
By: /s/ Raymond W. Anderson
-------------------------------------------------
Raymond W. Anderson
Chief Operating Officer, Chief Financial Officer,
Secretary and Vice President Finance and
Administration
Date: September 6, 2001
Exhibit Index
EXHIBIT NO. DESCRIPTION OF DOCUMENT
----------- ------------------------------------------------------------------
99.1 Press Release Dated September 6, 2001 related to completion of
MPS VI Phase I Trial.